Expert Opinion on Biological Therapy · 2020 · 137 citations · 104 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyCombination ImmunotherapyImmunotherapy For Solid TumorsTumor-associated AntigensCar T Cell TrialsInfiltrationSolid Tumor Car T-cell TherapySolid Tumor Cell TherapyT Cell-based ImmunotherapyTherapeutic Target IdentificationTumor Antigen PersistenceTumor Immune Cell Infiltration
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body’s mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged as an important target for the development of novel immunotherapies. This review focuses on anti-MSLN chimeric antigen receptor (CAR) T cell immunotherapy approaches.Areas covered: A brief overview of MSLN as a therapeutic target and existing anti-MSLN antibody-based drugs and vaccines is provided. A detailed account of anti-MSLN CAR-T cell approaches utilized in preclinical models is presented. Finally, a comprehensive summary of currently ongoing and completed anti-MSLN CAR-T cell clinical trials is discussed.Expert opinion: Initial trials using anti-MSLN CAR-T cells have been safe, but efficacy has been limited. Employing regional routes of delivery, introducing novel modifications leading to enhanced tumor infiltration and persistence, and improved safety profiles and combining anti-MSLN CAR-T cells with standard therapies, could render them more efficacious in the treatment of solid malignancies.
104
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis et al. · Nature · 2017 · 1.8K citations · Full text
Carmine Carpenito, Michael C. Milone, Raffit Hassan et al. · Proceedings of the National Academy of Sciences · 2009 · 889 citations · Full text
Life Sciences, Immunology, Oncology +17